F005 Skin Disease in Transplant Recipients and Immunosuppressed Patients
DESCRIPTION
Organ transplant recipients and other immunosuppressed patients have an increased risk of skin cancer development, progression, and death from skin cancer, as well as distinct presentations of inflammatory and infectious conditions. Dermatologists are uniquely positioned to care for these patients and optimize outcomes in the context of multidisciplinary care. This session will highlight key issues in the care of immunosuppressed patients, with a focus on prevention and management of multiple skin cancers, treatment of localized and advanced skin cancer, treatment of inflammatory and infectious skin disease, and recognition and mitigation of treatment fatigue.
LEARNING OBJECTIVES
Summarize recommendations for screening, detection and management of multiple skin cancers in transplant and immunosuppressed patients, recognizing the role of multidisciplinary care.
Prescribe topical and systemic therapy for treatment of precursor lesions and prevention of skin cancer in transplant and immunosuppressed patients.
Diagnose inflammatory and infectious skin disease in transplant and immunosuppressed patients, and identify factors that contribute to treatment fatigue and discontinuation in this population.
DIRECTOR
Sean Christensen, MD, PhD, FAAD
Yale University School of Medicine
SPEAKERS
Lihi Atzmony, MD, IFAAD
Samantha Guhan, MD, FAAD
Nina Ran, MD, MS, FAAD
Emily S. Ruiz, MD, FAAD
Annika P. Weinhammer, MD
Nathalie C. Zeitouni, MD, FAAD
DISCLOSURES
Lihi Atzmony, MD, IFAAD
No financial relationships exist with ineligible companies.
Sean Christensen, MD, PhD, FAAD
inhibitor therapeutics – Advisory Board(Fees); Natera – Advisory Board(Honoraria); Regeneron Pharmaceuticals Inc – Advisory Board(Honoraria); Sol-Gel Technologies – Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria);
Samantha Guhan, MD, FAAD
No financial relationships exist with ineligible companies.
Nina Ran, MD, MS, FAAD
Chronicle Medical Software – Consultant (1099 relationship)(Fees);
Emily S. Ruiz, MD, FAAD
Almirall – Consultant (1099 relationship)(Fees); Castle Biosciences, Inc – Investigator(Grants/Research Funding); Checkpoint Therapeutics – Consultant (1099 relationship)(Fees); Feldan Therapeutics – Consultant (1099 relationship)(Fees); Merck – Investigator(Grants/Research Funding); Regeneron – Advisory Board(Fees), Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees), Consultant (1099 relationship)(Fees);
Annika P. Weinhammer, MD
No financial relationships exist with ineligible companies.
Nathalie C. Zeitouni, MD, FAAD
Alpha Tau Medical – Investigator(Grants/Research Funding); Biofrontera AG – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Castle Biosciences – Investigator(Grants/Research Funding), Speaker(Honoraria); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Replimune – Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria), Investigator(Grants/Research Funding);